糖萼损伤对炎症性肠病的诊断和监测价值

doi:10.11958/20231646

天津医药 ›› 2024, Vol. 52 ›› Issue (8): 893-896.doi: 10.11958/20231646

• 综述 • 上一篇

糖萼损伤对炎症性肠病的诊断和监测价值

张乐丹¹(), 靳明星², 刘艳迪²^,^△()

1 南开大学医学院（邮编300071）
2 天津市人民医院消化科

收稿日期:2023-11-14 修回日期:2024-02-28 出版日期:2024-08-15 发布日期:2024-08-16
通讯作者: △E-mail：liuyandi66@163.com
作者简介:张乐丹（1999），女，硕士在读，主要从事炎症性肠病方面研究。E-mail：zhangledan666@163.com

Advances in the diagnostic and monitoring value of glycocalyx injury in inflammatory bowel disease

ZHANG Ledan¹(), JIN Mingxing², LIU Yandi²^,^△()

1 School of Medicine, Nankai University, Tianjin 300071, China
2 Department of Gastroenterology, Tianjin Union Medical Center

Received:2023-11-14 Revised:2024-02-28 Published:2024-08-15 Online:2024-08-16
Contact: △E-mail：liuyandi66@163.com

张乐丹, 靳明星, 刘艳迪. 糖萼损伤对炎症性肠病的诊断和监测价值[J]. 天津医药, 2024, 52(8): 893-896.

ZHANG Ledan, JIN Mingxing, LIU Yandi. Advances in the diagnostic and monitoring value of glycocalyx injury in inflammatory bowel disease[J]. Tianjin Medical Journal, 2024, 52(8): 893-896.

摘要/Abstract

摘要：

炎症性肠病（IBD）目前无法治愈，只能通过药物、手术等手段缓解症状，延缓和减少复发，因此对疾病活动度的监测至关重要。糖萼是覆盖于血管内皮细胞管腔侧的多糖蛋白复合物，对于维持肠道黏膜屏障具有支持作用，而炎症会导致其结构受损。该文介绍了目前临床上IBD在实验室检测中的无创性生物标志物，并分析了血清糖萼损伤标志物多配体蛋白聚糖1、硫酸乙酰肝素、透明质酸对IBD的诊断和监测价值。

关键词: 炎性肠疾病, 肠黏膜, 多配体蛋白聚糖1, 硫酸乙酰肝素, 透明质酸, 糖萼损伤

Abstract:

Inflammatory bowel disease (IBD) is no cure at present, and only drugs and surgery can relieve symptoms, delay and reduce recurrence. Therefore, it is very important to monitor the disease activity. Glycocalyx, a polyglycoprotein complex covering luminal side of vascular endothelial cells, is supportive in maintaining the intestinal mucosal barrier, and inflammation leads to its structural damage. This review introduces currently available non-invasive biomarkers of clinical importance for IBD in laboratory testing, and analyzes the value of serum glycocalyx injury markers (syndecan-1, HS and HA) in the diagnosis or monitoring of IBD.

Key words: inflammatory bowel diseases, intestinal mucosa, syndecan-1, heparitin sulfate, hyaluronic acid, glycocalyx damage

中图分类号:

R446.1，R574.6

参考文献 40

[1]	COLLABORATORS G I B D. The global,regional, and national burden of inflammatory bowel disease in 195 countries and territories,1990-2017:a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet Gastroenterol Hepatol, 2020, 5(1):17-30. doi:10.1016/S2468-1253(19)30333-4.
[2]	BRUSCOLI S, FEBO M, RICCARDI C, et al. Glucocorticoid therapy in inflammatory bowel disease:mechanisms and clinical practice[J]. Front Immunol, 2021, 12:691480. doi:10.3389/fimmu.2021.691480.
[3]	CORNISH J S, WIRTHGEN E, DABRITZ J. Biomarkers predictive of response to thiopurine therapy in inflammatory bowel disease[J]. Front Med(Lausanne), 2020, 7:8. doi:10.3389/fmed.2020.00008.
[4]	SCHOULTZ I, KEITA A V. The intestinal barrier and current techniques for the assessment of gut permeability[J]. Cells, 2020, 9(8):1909. doi:10.3390/cells9081909.
[5]	QU J, CHENG Y, WU W, et al. Glycocalyx impairment in vascular disease:focus on inflammation[J]. Front Cell Dev Biol, 2021, 9:730621. doi:10.3389/fcell.2021.730621.
[6]	XIE Z, BORSET M, SVEEN K, et al. Markers of endothelial glycocalyx dysfunction in Clarkson disease[J]. J Transl Med, 2022, 20(1):380. doi:10.1186/s12967-022-03587-1.
[7]	GRONDIN J A, KWON Y H, FAR P M, et al. Mucins in intestinal mucosal defense and inflammation:learning from clinical and experimental studies[J]. Front Immunol, 2020, 11:2054. doi:10.3389/fimmu.2020.02054.
[8]	ISKANDAR H N, CIORBA M A. Biomarkers in inflammatory bowel disease:current practices and recent advances[J]. Transl Res, 2012, 159(4):313-325. doi:10.1016/j.trsl.2012.01.001.
[9]	CHEN Y H, WANG L, FENG S Y, et al. The relationship between C-reactive protein/albumin ratio and disease activity in patients with inflammatory bowel disease[J]. Gastroenterol Res Pract, 2020,2020:3467419. doi:10.1155/2020/3467419.
[10]	LIU D, SAIKAM V, SKRADA K A, et al. Inflammatory bowel disease biomarkers[J]. Med Res Rev, 2022, 42(5):1856-1887. doi:10.1002/med.21893.
[11]	GUO X, HUANG C, XU J, et al. Gut microbiota is a potential biomarker in inflammatory bowel disease[J]. Front Nutr, 2021, 8:818902. doi:10.3389/fnut.2021.818902.
[12]	AITTAN E, GRALNEK I M, BERNS M S. The new proactive approach and precision medicine in Crohn's disease[J]. Biomedicines, 2020, 8(7):193. doi:10.3390/biomedicines8070193.
[13]	MURRAY J, KOK K B, AYLING R M. Fecal calprotectin in gastrointestinal disease[J]. Clin Chem, 2023, 69(7):699-710. doi:10.1093/clinchem/hvad051.
[14]	FREEMAN K, WILLIS B H, FRASER H, et al. Faecal calprotectin to detect inflammatory bowel disease:a systematic review and exploratory meta-analysis of test accuracy[J]. BMJ Open, 2019, 9(3):e27428. doi:10.1136/bmjopen-2018-027428.
[15]	HU Z, CANO I, D’AMORE P A. Update on the role of the endothelial glycocalyx in angiogenesis and vascular inflammation[J]. Front Cell Dev Biol, 2021, 9:734276. doi:10.3389/fcell.2021.734276.
[16]	FRANCEKOVIĆ P, GLIEMANN L. Endothelial glycocalyx preservation-impact of nutrition and lifestyle[J]. Nutrients, 2023, 15(11):2573. doi:10.3390/nu15112573.
[17]	YANG J, LEBLANC M E, CANO I, et al. ADAM10 and ADAM17 proteases mediate proinflammatory cytokine-induced and constitutive cleavage of endomucin from the endothelial surface[J]. J Biol Chem, 2020, 295(19):6641-6651. doi:10.1074/jbc.RA119.011192.
[18]	PUCHWEIN-SCHWEPCKE A, GENZEL-BOROVICZENY O, NUSSBAUM C. The endothelial glycocalyx:physiology and pathology in neonates,infants and children[J]. Front Cell Dev Biol, 2021, 9:733557. doi:10.3389/fcell.2021.733557.
[19]	DOGNE S, FLAMION B. Endothelial glycocalyx impairment in disease:focus on hyaluronan shedding[J]. Am J Pathol, 2020, 190(4):768-780. doi:10.1016/j.ajpath.2019.11.016.
[20]	YANY Y, SCHMIDT E P. The endothelial glycocalyx:an important regulator of the pulmonary vascular barrier[J]. Tissue Barriers, 2013, 1(1):e23494. doi:10.4161/tisb.23494.
[21]	AN J, LIU Y, WANG Y, et al. The role of intestinal mucosal barrier in autoimmune disease:a potential target[J]. Front Immunol, 2022, 13:871713. doi:10.3389/fimmu.2022.871713.
[22]	SCHNEIDER H, PELASEYED T, SEVNSSON F, et al. Study of mucin turnover in the small intestine by in vivo labeling[J]. Sci Rep, 2018, 8(1):5760. doi:10.1038/s41598-018-24148-x.
[23]	MARTENS E C, NEUMANN M, DESAI M S. Interactions of commensal and pathogenic microorganisms with the intestinal mucosal barrier[J]. Nat Rev Microbiol, 2018, 16(8):457-470. doi:10.1038/s41579-018-0036-x.
[24]	PARAY B A, ALBESHR M F, JAN A T, et al. Leaky gut and autoimmunity:an intricate balance in individuals health and the diseased state[J]. Int J Mol Sci, 2020, 21(24):9770. doi:10.3390/ijms21249770.
[25]	SEGRIST E, CHERRY S. Using diverse model systems to define intestinal epithelial defenses to enteric viral infections[J]. Cell Host Microbe, 2020, 27(3):329-344. doi:10.1016/j.chom.2020.02.003.
[26]	HANSSON G C. Mucins and the microbiome[J]. Annu Rev Biochem, 2020,89:769-793. doi:10.1146/annurev-biochem-011520-105053.
[27]	LI H, HAO Y, YANG L L, et al. MCTR1 alleviates lipopolysaccharide-induced acute lung injury by protecting lung endothelial glycocalyx[J]. J Cell Physiol, 2020, 235(10):7283-7294. doi:10.1002/jcp.29628.
[28]	HU C, LIAO S, LV L, et al. Intestinal immune imbalance is an alarm in the development of IBD[J]. Mediators Inflamm, 2023,2023:1073984. doi:10.1155/2023/1073984.
[29]	MAGRO D O, KOTZE P G, MARTINEZ C A R, et al. Changes in serum levels of lipopolysaccharides and CD26 in patients with Crohn's disease[J]. Intest Res, 2017, 15(3):352-357. doi:10.5217/ir.2017.15.3.352.
[30]	LAYUNTA E, JAVERFELT S, DOLAN B, et al. IL-22 promotes the formation of a MUC17 glycocalyx barrier in the postnatal small intestine during weaning[J]. Cell Rep, 2021, 34(7):108757. doi:10.1016/j.celrep.2021.108757.
[31]	VILLALBA N, BABY S, YUAN S Y. The endothelial glycocalyx as a double-edged sword in microvascular homeostasis and pathogenesis[J]. Front Cell Dev Biol, 2021, 9:711003. doi:10.3389/fcell.2021.711003.
[32]	NIGHOT M, GANAPATHY A S, SAHA K, et al. Matrix metalloproteinase MMP-12 promotes macrophage transmigration across intestinal epithelial tight junctions and increases severity of experimental colitis[J]. J Crohns Colitis, 2021, 15(10):1751-1765. doi:10.1093/ecco-jcc/jjab064.
[33]	LIN J C, WU J Q, WANG F, et al. QingBai decoction regulates intestinal permeability of dextran sulphate sodium-induced colitis through the modulation of notch and NF-κB signalling[J]. Cell Prolif, 2019, 52(2):e12547. doi:10.1111/cpr.12547.
[34]	WU D, ZHOU J, CREYER M N, et al. Phenolic-enabled nanotechnology:versatile particle engineering for biomedicine[J]. Chem Soc Rev, 2021, 50(7):4432-4483. doi:10.1039/d0cs00908c.
[35]	POLEDNICZEK M, NEUMAYER C, KOPP C W, et al. Micro- and macrovascular effects of inflammation in peripheral artery disease-pathophysiology and translational therapeutic approaches[J]. Biomedicines, 2023, 11(8):2284. doi:10.3390/biomedicines11082284.
[36]	MILUSEV A, DESPONT A, SHAW J, et al. Inflammatory stimuli induce shedding of heparan sulfate from arterial but not venous porcine endothelial cells leading to differential proinflammatory and procoagulant responses[J]. Sci Rep, 2023, 13(1):4483. doi:10.1038/s41598-023-31396-z.
[37]	TAGHAVI S, ABDULAH S, SHAHEEN F, et al. Glycocalyx degradation and the endotheliopathy of viral infection[J]. PLoS One, 2022, 17(10):e0276232. doi:10.1371/journal.pone.0276232.
[38]	DERKACZ A, OLCZYK P, OLCZYK K, et al. The role of extracellular matrix components in inflammatory bowel diseases[J]. J Clin Med, 2021, 10(5):1122. doi:10.3390/jcm10051122.
[39]	DERKACZ A, OLCZYK P, JURA-POLTORAK A, et al. The diagnostic usefulness of circulating profile of extracellular matrix components:sulfated glycosaminoglycans(sGAG),hyaluronan(HA) and extracellular part of Syndecan-1(sCD138) in patients with Crohn's disease and ulcerative colitis[J]. J Clin Med, 2021, 10(5):1122. doi:10.3390/jcm10051122.
[40]	FLOER M, CLAUSEN M, MEISTER T, et al. Soluble syndecan-1 as marker of intestinal inflammation:a preliminary study and evaluation of a new panel of biomarkers for non-invasive prediction of active ulcerative colitis[J]. Adv Clin Exp Med, 2021, 30(7):655-660. doi:10.17219/acem/139040.

糖萼损伤对炎症性肠病的诊断和监测价值

Advances in the diagnostic and monitoring value of glycocalyx injury in inflammatory bowel disease

引用本文

RichHTML

PDF (PC)

可视化

摘要/Abstract

使用本文

参考文献 40

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张萌, 崔瑞洁, 李彩芳, 高琦, 李斐. 盐酸小檗碱片联合复方谷氨酰胺对溃疡性结肠炎患者肠黏膜屏障功能的影响[J]. 天津医药, 2024, 52(1): 102-106.
[2]	刘青, 朱军, 唐国英, 蒋萍影. 肾病综合征患儿血清ET-1、SDC-1水平及其与激素治疗反应的相关性研究[J]. 天津医药, 2023, 51(4): 413-417.
[3]	冯颂乔, 何业伟, 王妍. 脓毒症所致的ALI/ARDS患者血浆SIRT-1、syndecan-1的表达水平及其对预后的影响[J]. 天津医药, 2023, 51(3): 311-314.
[4]	孙强, 宋维亮. 新型冠状病毒肺炎对肠道微生物群及肠黏膜屏障缺陷影响机制的研究进展[J]. 天津医药, 2023, 51(1): 105-108.
[5]	李娟, 袁向飞 , 赵煜 . 小肠结肠炎综合征小鼠肠黏膜中NLRP3表达与炎症分子关系的研究[J]. 天津医药, 2021, 49(8): 829-832.
[6]	刘晓敏, 孙慧莹, 王永福, 鲁芙爱 . HA、ColⅣ、LN和PⅢNP-P在结缔组织病合并间质性肺病病情评估中的意义[J]. 天津医药, 2021, 49(6): 617-621.
[7]	张红涛 1， 2，于洋 1，刘玲玲 2，于泳浩 1△，王国林 1. JNK 在氢气改善重度脓毒症小鼠肠屏障功能障碍中的作用[J]. 天津医药, 2016, 44(5): 573-576.
[8]	陈霞，赵宏贤，王巧稚，李昌平. 大黄素对重症急性胰腺炎肠黏膜屏障的保护作用及机制[J]. 天津医药, 2015, 43(12): 1398-1400.
[9]	高婷詹江华. CD38、CD138、IgG₄在胆道闭锁发病中作用的研究进展[J]. 天津医药, 2015, 43(12): 1460-1463.
[10]	王倩1 ,吕永慧2 ,周丽梅1 ,陈文剑2 ,江桂英1 ,江沂1 . Bcl-2与Caspase-3在溃疡性结肠炎中的表达与意义*[J]. , 2013, (9): 849-851 .
[11]	张凤1 ,徐旭娟2 ,沈美云3 . 肝性脑病食醋灌肠导致肠黏膜屏障损伤及改进方法[J]. , 2013, (9): 901-903 .
[12]	刘新兰1 ,赵艳姣2 ,马志兰3 . VEGF-C、VEGFR-3 和 LYVE-1 的表达在胃癌淋巴管生成及预后中的作用[J]. , 2013, 41(8): 0-746 .
[13]	王艳荣. 美洲大蠊提取物对实验性肝纤维化大鼠的保护作用[J]. , 2013, (12): 1195-1198 .
[14]	常文秀1 ,曹书华2 ,王勇强3 ,杨书英1 . 凉膈散对肠缺血再灌注损伤大鼠肠道的保护作用[J]. , 2012, 40(4): 370-374 .
[15]	张丽丽. 体外循环对瓣膜置换术患者肠黏膜屏障功能的影响[J]. , 2012, 40(3): 0-214 .